European Association for the Study of Diabetes

28/08/2026

📻 As we count down to , we're revisiting some of our favourite EASD Live conversations straight from our archives!

This one: "The Future of Diabetes Technology: Beyond Devices to Equity and Personalisation" brings together Anna Krook, Klemen Dovč, Pieter Gillard and Julia Mader to explore how diabetes technology is moving beyond devices: from CGM and automated insulin delivery to AI, personalisation and integrated health records.

The conversation also asks an important question: how do we ensure that these innovations are accessible to everyone?

📺 Watch: https://www.youtube.com/watch?v=idH5R7AAN9w&list=PLTBi1c0HF5qPUCItbgCQk68yIon8qtkov&index=18&t=7s
🎧 Listen: https://diabetes-insights.podigee.io/32-the-future-of-diabetes-technology-beyond-devices-to-equity-and-personalisation

27/08/2026

🤔 Does lifestyle intervention really need to come first?

Many clinical guidelines require patients to complete a period of lifestyle intervention before starting obesity pharmacotherapy - but where does that rule actually come from?

In a new opinion piece in Metabologia, Luiz F. Viola et al. make the case that this requirement has never been prospectively tested. They point out that obesity drug trials show pharmacotherapy is the main driver of weight loss, and draw a parallel to bariatric surgery, where mandatory preoperative lifestyle intervals have already been abandoned.

A timely read for anyone involved in obesity care guidelines or treatment. 📖

🔗 Read the full article: https://doi.org/10.1007/s44357-026-00012-8

Many clinical guidelines require a period of lifestyle intervention before initiating obesity management medications. No prospective trial has tested whether this sequence improves outcomes compared with concomitant initiation. The rule likely originated from the duration of behavioural intervention...

27/08/2026

📢 🎤 𝐒𝐏𝐄𝐀𝐊𝐄𝐑 𝐇𝐈𝐆𝐇𝐋𝐈𝐆𝐇𝐓: Everything you want to know about future challenges in obesity management

Join Prof. Timo Müller, who was also a 2023 Minkowski Prize Awardee, (Helmholtz Munich) at the EASD Annual Meeting 2026 in Milan for his presentation titled: "Did we already reach the maximum effect size of pharmacotherapies?" 💊

📅 Thursday, 1 October 2026 | 🕒 08:45 - 09:00 CEST |📍London Hall

Mark your calendar and spread the word 👉 https://pagv3.virtual-meeting.org/easd/easd2026/en-GB/pag/presentation/268845?view=list&q=did+we+already&segment=presentations&sort=starts_at&fullscreen=1

Expect expert insights, practical relevance, and a session you won't want to miss.

26/08/2026

📢 𝐋𝐀𝐒𝐓 𝐂𝐀𝐋𝐋! 𝐖𝐄'𝐑𝐄 𝐇𝐈𝐑𝐈𝐍𝐆!

We are looking for a motivated, enthusiastic and suitably qualified Administrator (m/f/d) to join our Education Department on a full-time basis.

If you're organised, detail-oriented and keen to support diabetes education initiatives at an international level, we'd love to hear from you.

📅 Apply by 31 August 2026

🔗 👉 Learn more and apply now:https://www.easd.org/uploads/JobAd_Administrator_Education_2026.pdf

26/08/2026

✋ Taking care of young adults diagnosed with type 2 diabetes may be facing a rather overlooked challenge: strikingly low physical activity.

🏃‍♀️ A new accelerometer-based analysis published in Metabologia found that, at age 20, people with newly diagnosed type 2 diabetes averaged an estimated only 16 minutes of moderate-to-vigorous activity per day, compared with 49 minutes among peers without diabetes. They also recorded roughly half as many daily steps.

⭐️ The study reinforces why 24-hour behaviours (movement, sedentary time and sleep) should be central to prevention and person-centred management, particularly for early-onset type 2 diabetes, first-author Jonathan Goldney from Leicester Diabetes Centre emphasises.

👉 Read the EASD e-Learning Journal Read to explore the findings, their limitations, and why tailored intervention studies are now urgently needed on the EASD e-Learning platform: 🔗 https://easd-elearning.eu/news/478/Type-2-diabetes-onset-in-young-adults.html

25/08/2026

🧠 Meet Prof. John Dennis (University of Exeter), recipient of the EASD Rising Star Symposium & Rising Star Research Fellowship.

His project, “Individual-level heart failure risk stratification to inform precision SGLT2-inhibitor treatment,” focuses on identifying people with type 2 diabetes who are most likely to benefit from SGLT2 inhibitors for the prevention of heart failure and kidney disease.

The research has resulted in validated prediction models that use routine clinical information to estimate an individual’s likely benefit from SGLT2-inhibitor treatment. By providing personalised estimates of risk reduction, this work could help support more precise treatment decisions and identify those most likely to benefit.

🗣️ “The EFSD programme has helped progress my career as an independent diabetes researcher and lead precision medicine research that can make a real difference to people with type 2 diabetes.”- Reflecting on the programme, Prof. Dennis shares!

📖 Read the research 👉 https://link.springer.com/article/10.1007/s00125-025-06577-2

💡 Explore EFSD programmes 👉 https://www.europeandiabetesfoundation.org/programmes/

Supported by Novo Nordisk.

25/08/2026

🧠 Great discussions and inspiring science at the 29th EASD Oxford Workshop on Organ Crosstalk which was held on 📅14 - 17 August 2026 and hosted at Keble College, Oxford.

Led by Workshop Coordinators Sanna Lehtonen and Hadi Al-Hasani, with Co-Chairs Alexandra Chadt and Martin Heni. The meeting brought together leading international experts and emerging researchers to shape future directions in the field through collaboration, innovation, and tandem senior-junior presentations.

See more: https://www.easd.org/education/meetings-and-courses/oxford-workshop/

24/08/2026

⏰ Reminder: Applications for the EASD Guideline Development Panel (GDP) on the Management of Diabetes in Older Adults close soon.

This panel will help shape clinical guidance for one of the most complex and fast-growing areas of diabetes care, supporting better outcomes for older adults living with diabetes worldwide.

🩺 We're looking for clinicians, researchers and other experts with relevant experience in this field to contribute their knowledge and perspective

📅 Application Deadline: 31 August 2026

🔗👉 Learn more and apply here: https://www.easd.org/guidelines/statements-guidelines/management-of-diabetes-in-older-adults/

21/08/2026

⏰ 𝐅𝐢𝐧𝐚𝐥 𝐫𝐞𝐦𝐢𝐧𝐝𝐞𝐫: applications for the inaugural EASD AI Workshop are nearing their deadline soon.

📍“Artificial Intelligence in Diabetes Care: From Foundations to Clinical Practice” is EASD's first dedicated AI workshop, held before the start of in Milan on Sunday, 27 September 2026.

📅 Applications close: 26 August 2026 | 🕛 17:00 CEST

This is your last chance to apply for a half-day, interactive pre-conference workshop covering predictive, generative and agentic AI, AI-powered diabetes technology, responsible AI and hands-on prompting exercises (No previous AI or programming experience required).

👉 Learn more and send your complete application: https://www.easd.org/education/meetings-and-courses/ai-workshop-2026/

21/08/2026

📻 As we count down to , we're revisiting some of our favourite EASD Live conversations straight from our archives!

This one: "Targeting mitochondria to treat diabetes and heart disease" from Prof. Gerald I. Shulman (Yale School of Medicine), 11th recipient of the EASD - Novo Nordisk Foundation Diabetes Prize for Excellence, talked us through four decades of research into mitochondria, insulin resistance, and where the field is heading next.

📺 Watch: https://www.youtube.com/watch?v=CEb9gPAkIcI&t=1s

🎧 Listen: https://diabetes-insights.podigee.io/33-mitochondria-insulin-resistance-and-the-future-of-diabetes-treatment-with-prof-jerry-shulman